The content is available as a PDF (308.5 KB).
. 2021 Apr 2:jfab027. doi: 10.1093/jalm/jfab027
Serology testing demonstrates that antibodies to SARS-CoV-2 S1-RBD correlate with neutralization of virus infection of Vero E6 cells
James Freeman
1,✉, Justin Conklin
1, Diana Oramus
2, Kelly Cycon
2
James Freeman
1
Siemens Healthcare Diagnostics Inc, Tarrytown, New York, United States
Find articles by James Freeman
Justin Conklin
1
Siemens Healthcare Diagnostics Inc, Tarrytown, New York, United States
Find articles by Justin Conklin
1
Siemens Healthcare Diagnostics Inc, Tarrytown, New York, United States
2
ZeptoMetrix, Buffalo, New York, United States
✉
Correspondence: James Freeman, Siemens Healthcare Diagnostics Inc, 511 Benedict Ave, Tarrytown, New York 10591, United States, Phone: 1(914)524-2902, Email: james.freeman@siemens-healthineers.com
Received 2020 Nov 30; Accepted 2021 Mar 15.
Keywords: neutralization, antibody, SARS-CoV-2, COVID-19, Vero E6, serology
© 2021 American Association for Clinical Chemistry
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC8083479 PMID: 33822063